Navigation Links
Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
Date:10/13/2011

of MDS.  Telintra has the potential for combining with other agents used to treat MDS.  Telintra has been well-tolerated with mostly grade 1 or 2 gastrointestinal side effects.

Background on MDS and Telintra

The myelodysplastic syndrome is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more cell lineages (red blood cells, white blood cells or platelets) and a variable risk of transformation to acute myeloid leukemia.  It is estimated that MDS affects approximately 300,000 people worldwide. According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years. MDS patients often require multiple blood transfusions to manage their disease.

Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1, which leads to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells; and induces cancer cell death, or apoptosis, in human leukemia cell lines. Telintra is also being evaluated in a Phase 2 clinical study in Revlimid® refractory and resistant deletion 5q MDS patients.  Additional information about Telintra is available at www.telik.com.

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery tech
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
2. Telik Announces First Quarter 2011 Financial Results
3. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
4. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
5. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
6. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
7. Telik Announces Presentation at American Society of Hematology Annual Meeting
8. Telik Announces Third Quarter 2010 Financial Results
9. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
10. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
11. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... YORK , April 21, 2015 EpiCast ... Summary Sepsis is a life-threatening complication arising from ... the infection damages its own tissues and organs. Anyone ... among children <1 year of age, older ... 2014). Global estimates for the year 2013 showed that ...
(Date:4/21/2015)... -- Global cap & closure demand to ... and closures will exceed $55 billion in 2019. In unit ... Beverages will continue to account for well over half of ... smaller markets are expected to register faster growth. ... developed markets -- the US, Western Europe ...
(Date:4/21/2015)... 21, 2015 Gary A. Puckrein , ... Quality Forum (NMQF), today will present an award ... Pharmaceutical Research and Manufacturers of America (PhRMA), for ... On behalf of PhRMA, and in conjunction with NMQF, ... build awareness, start conversations, and increase diversity in clinical ...
Breaking Medicine Technology:EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3World Caps & Closures Market 2World Caps & Closures Market 3National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 2National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 3
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:4/21/2015)... April 21, 2015 On April 2, ... Trying to Achieve Kylie Jenner Lips With ... have injured themselves while attempting an at-home lip ... Twitter is that creating an airlock around one’s mouth ... to plump and achieve Kylie Jenner’s now famous pout. ...
(Date:4/21/2015)... Texas (PRWEB) April 22, 2015 ... Review, H1 2015” provides comparative analysis on ... report strengthens R&D pipelines by identifying new ... best-in-class products. Complete report with TOC is ... The report also reviews key players involved ...
(Date:4/21/2015)... The California Healthcare Institute (CHI), ... sciences organizations, released the following statement by CHI ... Assembly Bill (AB) 463: , “As innovators in ... of treatments and cures for patients with serious ... AB 463, the so-called Pharmaceutical Cost Transparency Act ...
(Date:4/21/2015)... Vancouver, BC (PRWEB) April 21, 2015 ... offers complimentary pick-up and delivery for clients that avail ... South Surrey by Angelo’s is done with hi-tech equipments, ... inconvenience for customers. They use all natural, high pressure ... as well as hand washing for area rugs made ...
(Date:4/21/2015)... Danvers, MA (PRWEB) April 21, 2015 ... managed mobility services, has been recognized by the Boston ... Massachusetts. The ranking was announced at a recent ... Journal’s annual list of the fastest-growing private companies in ... held businesses in the state that recorded the fastest ...
Breaking Medicine News(10 mins):Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:California Healthcare Institute Statement on AB 463 2Health News:California Healthcare Institute Statement on AB 463 3Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2
... 2 MedWaves, Inc. announces the receipt of ... is in addition to having already received U.S. ... Microwave Coagulation/Ablation System for surgical applications. The system ... interventional radiologists to treat soft tissue problems, such ...
... BEACH, Va., Feb. 2 AMERIGROUP Corporation (NYSE: ... plan in the State of Nevada began offering healthcare ... Children,s Health Insurance (SCHIP) programs beginning February 1, 2009. ... of Nevada," said James G. Carlson, AMERIGROUP Chairman and ...
... in customer and technical supportPORTLAND, Ore., Feb. 2 ... Vice President of Customer Support. With nearly 20 years ... managing customer inquiries, special service requests, and technical support ... leadership, she has also developed new programs to smooth ...
... Opportunity Partners, LLC ("Xmark"), the sole member of the investment ... Ltd., has, in the past, sent letters to the Board ... setting forth its dissatisfaction with the company,s corporate governance, management ... opportunity to respond to the Form 8-K filed by the ...
... Mich., Feb. 2 Dorothy Carpenter had stomach problems her ... or pasta could lead to terrible pain.Her illness went undiagnosed ... System physician recognized it as celiac disease. By then her ... forced doctors to remove part of her small intestine."I,ve been ...
... JOLLA, Calif., Feb. 2 Transdel Pharmaceuticals, ... ), a specialty pharmaceutical company focused on ... has retained FLP Pharma, a Georgia-based pharmaceutical ... especially the out-licensing of its lead product ...
Cached Medicine News:Health News:MedWaves, Inc. Announces Receipt of MDD CE Certification and Additional U.S. FDA 510(k) Clearance to Market Its Patented Microwave Coagulation/Ablation System and Devices 2Health News:AMERIGROUP Health Plan in Nevada Begins Serving Medicaid Enrollees 2Health News:GI Condition Once Thought Rare is Common in U.S. 2Health News:GI Condition Once Thought Rare is Common in U.S. 3Health News:Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities 2Health News:Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities 3
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
Rapid immunochromatographic membrane test for RSV. Accepts nasopharyngeal washes, aspirates, and swabs....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: